Literature DB >> 22874134

A perspective on the evidence regarding methicillin-resistant Staphylococcus aureus surveillance.

Kevin Kavanagh1, Said Abusalem, Daniel M Saman.   

Abstract

Two prominent studies have been used by policy makers to prevent the enactment of standards of care regarding active surveillance of patients with methicillin-resistant Staphylococcus aureus in hospital settings. In this brief review and perspective of those studies, we contend that both studies have serious limitations (i.e., the intervention group was not given optimal intervention) that may not have been scrutinized by many policy makers, health officials, and other researchers. These studies seem to have had a disproportionate impact on health-care policy despite their limitations. Furthermore, health-care policy and treatment standards need to reflect the preponderance of evidence with appropriate weight given to research studies based on their strengths and limitations. Only then can treatment standards that are effective against methicillin-resistant Staphylococcus aureus be adopted or refuted.

Entities:  

Mesh:

Year:  2012        PMID: 22874134     DOI: 10.1097/PTS.0b013e3182627b89

Source DB:  PubMed          Journal:  J Patient Saf        ISSN: 1549-8417            Impact factor:   2.844


  3 in total

1.  A perspective on how the United States fell behind Northern Europe in the battle against methicillin-resistant Staphylococcus aureus.

Authors:  Kevin T Kavanagh; Daniel M Saman; Yanling Yu
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

2.  Viewpoint: a response to "Screening and isolation to control methicillin-resistant Staphylococcus aureus: sense, nonsense, and evidence".

Authors:  Kevin T Kavanagh; Lindsay E Calderon; Daniel M Saman
Journal:  Antimicrob Resist Infect Control       Date:  2015-02-05       Impact factor: 4.887

3.  Control of MSSA and MRSA in the United States: protocols, policies, risk adjustment and excuses.

Authors:  Kevin T Kavanagh
Journal:  Antimicrob Resist Infect Control       Date:  2019-06-19       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.